Abstract

Motivation: To test the validity of the ALPS index as a biomarker for VCIDGoal(s): To test our hypothesis that ALPS index is an independent biomarker for the cognitive decline in cSVD. Approach: Participants from MarkVCID consortium underwent baseline and follow-up MRI examinations and clinical evaluations of cognitive functionResults: We found the baseline ALPS index was correlated with the existing biomarkers of cSVD and VCID, and was independently associated with the baseline cognitive performanceImpact: Our study provides the clinical validation of the ALPS index as a sensitive and independent biomarker for the cognitive function of cSVD related VCID.